Generated Narrative: Citation 179617 version: 20; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). identifier: FEvIR Object Identifier/179617, https://pubmed.ncbi.nlm.nih.gov/25301760, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.51 version: 1.0.0-ballot3 title: 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). status: Active date: 2026-01-08 11:24:31+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base jurisdiction: World copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2016-04-07 lastReviewDate: 2022-12-08 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Received period: ?? --> 2014-07-23 statusDate activity: PubMed Pubstatus of Accepted period: ?? --> 2014-09-19 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2014-10-11 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2014-10-11 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2016-04-08 06:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/25301760, https://doi.org/10.1016/j.eururo.2014.09.032, pii/S0302-2838(14)00969-5 Titles - Type Text * Primary title Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Abstracts - Type Text Copyright * Primary human use BACKGROUND: Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort. OBJECTIVE: Describe survival outcomes, along with current treatment standards and factors associated with prognosis, to inform future trial design in this patient group. DESIGN, SETTING, AND PARTICIPANTS: STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who were recruited between October 2005 and January 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and failure-free survival (FFS) were reported by primary disease characteristics using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (CIs) were derived from multivariate Cox models. RESULTS AND LIMITATIONS: A cohort of 917 men with newly diagnosed M1 disease was recruited to the control arm in the specified interval. Median follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 34-373). Most men (n=574; 62%) had bone-only metastases, whereas 237 (26%) had both bone and soft tissue metastases; soft tissue metastasis was found mainly in distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% CI, 68-76). Survival time was influenced by performance status, age, Gleason score, and metastases distribution. Median survival after FFS event was 22 mo. Trial eligibility criteria meant men were younger and fitter than general PCa population. CONCLUSIONS: Survival remains disappointing in men presenting with M1 disease who are started on only long-term ADT, despite active treatments being available at first failure of ADT. Importantly, men with M1 disease now spend the majority of their remaining life in a state of castration-resistant relapse. PATIENT SUMMARY: Results from this control arm cohort found survival is relatively short and highly influenced by patient age, fitness, and where prostate cancer has spread in the body. Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved. relatesTo type: Has Comment In classifier: Comment citation: Eur Urol. 2015 Jun;67(6):1039-1041. doi: 10.1016/j.eururo.2014.12.004. relatesTo type: Has Comment In classifier: Comment citation: J Urol. 2016 Feb;195(2):350. doi: 10.1016/j.juro.2015.10.165. publicationForm publishedIn type: Periodical identifier: Electronic ISSN Type/1873-7560, ISOAbbreviation/Eur Urol, ISSN Linking/0302-2838, Medline Title Abbreviation/Eur Urol, NLM Unique ID/7512719 title: European urology publisherLocation: Switzerland citedMedium: Internet volume: 67 issue: 6 articleDate: 2015-06 pageString: 1028-1038 publicationForm citedMedium: Internet without issue articleDate: 2014-10-06 webLocation classifier: Abstract url: https://pubmed.ncbi.nlm.nih.gov/25301760/ webLocation classifier: DOI Based url: https://doi.org/10.1016/j.eururo.2014.09.032 classification type: Publishing Model classifier: Print Electronic classification type: Keyword artifactAssessment: Keywords provided by NOTNLM classification type: Chemical classifier: Androgen Antagonists, Taxoids, Docetaxel, Prostate-Specific Antigen classification type: MeSH heading artifactAssessment: ArtifactAssessment: artifact[x] = this resource classification type: Publication type classifier: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't classification type: Knowledge Artifact Type classifier: Journal Article artifactAssessment: Classifier added by Computable Publishing LLC classification type: Citation subset classifier: IM contributorship complete: true entry contributor: James ND forenameInitials: ND affiliation: University of Warwick, Coventry, UK. Electronic address: N.D.James@warwick.ac.uk. entry contributor: Spears MR forenameInitials: MR affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK. entry contributor: Clarke NW forenameInitials: NW affiliation: Department of Urology, The Christie NHS Foundation Trust, Manchester, UK. entry contributor: Dearnaley DP forenameInitials: DP affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. entry contributor: De Bono JS forenameInitials: JS affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. entry contributor: Gale J forenameInitials: J affiliation: Queen Alexandra Hospital, Portsmouth, UK. entry contributor: Hetherington J forenameInitials: J affiliation: Hull & East Yorkshire Hospitals NHS Trust, Hull, UK. entry contributor: Hoskin PJ forenameInitials: PJ affiliation: Mount Vernon Hospital, Northwood, Middlesex, UK. entry contributor: Jones RJ forenameInitials: RJ affiliation: University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. entry contributor: Laing R forenameInitials: R affiliation: Royal Surrey County Hospital, Guildford, UK. entry contributor: Lester JF forenameInitials: JF affiliation: Velindre Hospital, Cardiff, UK. entry contributor: McLaren D forenameInitials: D affiliation: Western General Hospital, Edinburgh, UK. entry contributor: Parker CC forenameInitials: CC affiliation: Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK. entry contributor: Parmar MKB forenameInitials: MKB affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK. entry contributor: Ritchie AWS forenameInitials: AWS affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK. entry contributor: Russell JM forenameInitials: JM affiliation: Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. entry contributor: Strebel RT forenameInitials: RT affiliation: Kantonsspital Graübunden, Chur, Switzerland. entry contributor: Thalmann GN forenameInitials: GN affiliation: Department of Urology, University Hospital, Bern, Switzerland. entry contributor: Mason MD forenameInitials: MD affiliation: Velindre Hospital, Cardiff, UK. entry contributor: Sydes MR forenameInitials: MR affiliation: Medical Research Council Clinical Trials Unit at University College London, London, UK. Generated Narrative: ArtifactAssessment #keywords0 artifact: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). content classifier: Control arm cohort content classifier: Hormone-naïve content classifier: Metastatic content classifier: Natural history content classifier: Prognostic factors content classifier: Prospective data content classifier: Prostate cancer content classifier: Survival content classifier: Time to progression Generated Narrative: Practitioner #contributor0 name: Nicholas David James Generated Narrative: Practitioner #contributor1 name: Melissa R Spears Generated Narrative: Practitioner #contributor2 name: Noel W Clarke Generated Narrative: Practitioner #contributor3 name: David P Dearnaley Generated Narrative: Practitioner #contributor4 name: Johann S De Bono Generated Narrative: Practitioner #contributor5 name: Joanna Gale Generated Narrative: Practitioner #contributor6 name: John Hetherington Generated Narrative: Practitioner #contributor7 name: Peter J Hoskin Generated Narrative: Practitioner #contributor8 name: Robert J Jones Generated Narrative: Practitioner #contributor9 name: Robert Laing Generated Narrative: Practitioner #contributor10 name: Jason F Lester Generated Narrative: Practitioner #contributor11 name: Duncan McLaren Generated Narrative: Practitioner #contributor12 name: Christopher C Parker Generated Narrative: Practitioner #contributor13 name: Mahesh K B Parmar Generated Narrative: Practitioner #contributor14 name: Alastair W S Ritchie Generated Narrative: Practitioner #contributor15 name: J Martin Russell Generated Narrative: Practitioner #contributor16 name: Räto T Strebel Generated Narrative: Practitioner #contributor17 name: George N Thalmann Generated Narrative: Practitioner #contributor18 name: Malcolm D Mason Generated Narrative: Practitioner #contributor19 name: Matthew R Sydes Generated Narrative: ArtifactAssessment #meshHeading0 artifact: Citation 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). content type: components (if present) include qualifier codings classifier: Adult freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Age Factors freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Aged, 80 and over freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Androgen Antagonists freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Cohort Studies freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Disease-Free Survival freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Docetaxel freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Early Detection of Cancer freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: mortality Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Follow-Up Studies freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Humans freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Kaplan-Meier Estimate freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Male freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Middle Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Neoplasm Grading freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Neoplasm Metastasis freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: diagnosis Components - Type Classifier * is Major topic No component type: qualifier classifier: pathology Components - Type Classifier * is Major topic No component type: qualifier classifier: therapy Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Physical Fitness freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Prognosis freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Proportional Hazards Models freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Prostate-Specific Antigen freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: blood Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Prostatic Neoplasms freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: diagnosis Components - Type Classifier * is Major topic No component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: mortality Components - Type Classifier * is Major topic No component type: qualifier classifier: pathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Risk Factors freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Taxoids freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Treatment Outcome freeToShare: true Components - Type Classifier * qualifier is not a major topic
components (if present) include qualifier codings
25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Computable Publishing®: MEDLINE-to-FEvIR Converter
HL7 International / Clinical Decision Support
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
National Library of Medicine, Index Section
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
**BACKGROUND:** Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort. **OBJECTIVE:** Describe survival outcomes, along with current treatment standards and factors associated with prognosis, to inform future trial design in this patient group. **DESIGN, SETTING, AND PARTICIPANTS:** STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who were recruited between October 2005 and January 2014. **OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:** Overall survival (OS) and failure-free survival (FFS) were reported by primary disease characteristics using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (CIs) were derived from multivariate Cox models. **RESULTS AND LIMITATIONS:** A cohort of 917 men with newly diagnosed M1 disease was recruited to the control arm in the specified interval. Median follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 34-373). Most men (n=574; 62%) had bone-only metastases, whereas 237 (26%) had both bone and soft tissue metastases; soft tissue metastasis was found mainly in distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% CI, 68-76). Survival time was influenced by performance status, age, Gleason score, and metastases distribution. Median survival after FFS event was 22 mo. Trial eligibility criteria meant men were younger and fitter than general PCa population. **CONCLUSIONS:** Survival remains disappointing in men presenting with M1 disease who are started on only long-term ADT, despite active treatments being available at first failure of ADT. Importantly, men with M1 disease now spend the majority of their remaining life in a state of castration-resistant relapse. **PATIENT SUMMARY:** Results from this control arm cohort found survival is relatively short and highly influenced by patient age, fitness, and where prostate cancer has spread in the body.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Classifier added by Computable Publishing LLC
University of Warwick, Coventry, UK. Electronic address: N.D.James@warwick.ac.uk.
Medical Research Council Clinical Trials Unit at University College London, London, UK.
Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.
Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
Queen Alexandra Hospital, Portsmouth, UK.
Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
Mount Vernon Hospital, Northwood, Middlesex, UK.
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Royal Surrey County Hospital, Guildford, UK.
Western General Hospital, Edinburgh, UK.
Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Kantonsspital Graübunden, Chur, Switzerland.
Department of Urology, University Hospital, Bern, Switzerland.